Latest News

Ceapro Inc. Announces Conversion of Convertible Debentures to Equity and the Grant of Stock Options

EDMONTON, ALBERTA – January 4, 2017 – Ceapro Inc.  (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that holders of $960,000 of convertible debentures due December 31, 2016 have […]

Read more

Ceapro Inc. to Present at Biotech Showcase™ 2017 – Presentation with live audio webcast on Monday, January 9th at 3:00 p.m. PT

EDMONTON, ALBERTA – January 3, 2017 – Ceapro Inc.  (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it will present at the 9th Annual Biotech Showcase™ conference on […]

Read more

Ceapro Inc. Reports Third Quarter 2016 Financial and Operational Results – Continued to deliver strong performance, surpassing the full year 2015 financial results by the third quarter of 2016 – Announced opening of new facility in Edmonton – Awarded “Company of the Year” by Bio Alberta

EDMONTON, ALBERTA – November 23, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the three-month and nine-month periods ended September 30, […]

Read more

Ceapro Inc. Announces the Grand Opening of New Bio-processing Extraction Facility

EDMONTON, ALBERTA – September 28, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the grand opening of its new 30,000-square-foot bioprocessing extraction/manufacturing facility in Edmonton, […]

Read more

Ceapro Inc. Awarded 2016 BioAlberta Achievement Award for Company of the Year

EDMONTON, ALBERTA – September 27, 2016 – Ceapro Inc.  (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the Company has been awarded the 2016 BioAlberta Achievement Award for […]

Read more

Ceapro Inc. Awarded Research Grant from German-Canadian Centre for Innovation and Research – Ceapro Enters into a multi-partners’ project through Alberta-Germany Collaboration Fund for Product Development and Commercialization of PGX Technology

EDMONTON, ALBERTA – September 21, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the German-Canadian Centre for Innovation and Research (“GCCIR”) has made a […]

Read more

Ceapro Inc. Announces Allowance of Canadian Patent for Enabling Pressurized Gas eXpanded (PGX) Technology

EDMONTON, ALBERTA – September 13, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the Company has received allowance from the Canadian Patent Office for […]

Read more

Ceapro Inc. Reports Second Quarter 2016 Financial and Operational Results – Ceapro completes another record-setting quarter for the highest quarterly revenues reported in Company’s history – Clinical program with avenanthramides as anti-inflammatory compound initiated

EDMONTON, ALBERTA – August 24, 2016 – Ceapro Inc.  (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the three-month and six-month periods ended June 30, […]

Read more

Ceapro Inc. Closes Final Tranche of a Brokered Private Placement

EDMONTON, ALBERTA – July 14, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has closed the second and final tranche of its previously […]

Read more

Ceapro Inc. Closes an Initial Tranche of a Brokered Private Placement

EDMONTON, ALBERTA – July 11, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has closed the first tranche of its previously announced brokered […]

Read more